Sansure Biotech announced that the company will invest CNY 90.93 million, accounting for 53.2% of the shares, and jointly establish Hunan Sansure Ansai Biotechnology.

Recently, the General Office of the State Council communicated Measures of Ministry of Commerce and the Ministry of Science and technology (MOST) for Further Encouraging Foreign Investment in Establishing Research and Development (R&D) Centers in China.

In March 2023, Cygnus received another round of Series C+ financing of hundreds of millions of RMB, led by Source Capital, and followed by Jianxin Equity, Yizhuang State Investment, Fangzhenghesheng, and Hetang Venture Capital.

TinkerBio completed a Series A+ financing round of tens of millions of RMB, exclusively invested by Panlin Capital.

Bioantibody has completed its first round of financing totaling nearly 100 million yuan. This financing was led by Fang Fund and followed by New Industry Investment, Guoqian Venture Investment, Bondshine Capital. Phoenix Tree Capital acted as the exclusive financial advisor.

Following the broader life science tools space, proteomics firms experienced something of a retrenchment in 2022 as the boom times of the previous two years gave way to layoffs, strategic realignments, and delays.

From December 15 to 22, the 7th "Guruclub Global Investment Carnival 2023" was grandly held. The Greater China Best Listed Companies has been announced and IVD companies Mindray, United Imaging Healthcare, YHLO, New Horizon Health, BGI Genomics, GenePlus, and Qitan Technology were on the list.

PBD Biotech said Monday it gained investment funding of ￡2.4 million ($2.7 million) to support clinical trials for its Actiphage rapid screening test for latent tuberculosis infections and their potential to develop into serious disease.

September 21, Merck, a leading global technology company, announced the opening of the first phase of its EUR 29 million biosafety testing laboratory in China, a virus clearance validation laboratory. The 5,000 square meter center is Merck's first laboratory of its kind in China.

Cytiva, backed by a $1.5 billion investment from its parent company, the Danaher Group, continued its expansion tear with the acquisition of CEVEC Pharmaceuticals.